This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richardson, P. G. Articles by Anderson, K. Search for Related Content PubMed PubMed Citation Articles by Richardson, P. G. Articles by Anderson, K.

Myelomas

New Drugs for Myeloma

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

Key Words. Bortezomib • Lenalidomide • Multiple myeloma • Thalidomide

Correspondence: Paul G. Richardson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Dana 1B02, Boston, Massachusetts 02115, USA. Telephone: 617-632-2104; Fax: 617-632-6624; e-mail: paul_richardson{at}dfci.harvard.edu

Although multiple myeloma remains incurable with conventional treatments, management of the disease has recently been transformed with the introduction of three novel agents, bortezomib, thalidomide, and lenalidomide. The proteasome inhibitor bortezomib is approved for the treatment of patients who have received one prior therapy; there is a growing body of clinical evidence showing its effectiveness alone and in combination in the frontline setting, with high response rates and consistently high rates of complete response. Thalidomide plus dexamethasone is approved as frontline treatment of multiple myeloma. Other combination regimens including thalidomide have demonstrated substantial activity in both relapsed and frontline settings. Recently, the thalidomide analogue lenalidomide has been approved, in combination with dexamethasone, for the treatment of patients who have received one prior therapy; this regimen has shown promising results in the frontline setting. These agents represent a new generation of treatments for multiple myeloma that affect both specific intracellular signaling pathways and the tumor microenvironment. Other novel, targeted therapies are also being evaluated in preclinical and clinical studies. Regimens incorporating bortezomib, thalidomide, lenalidomide, and other novel agents, together with commonly used conventional drugs, represent a promising future direction in myeloma treatment. At present, further investigation is required to assess the safety and activity of combinations integrating these other novel agents. However, bortezomib, thalidomide, and lenalidomide are now in widespread clinical use. This review therefore focuses on the extensive clinical data available from studies of these drugs in the treatment of newly diagnosed and advanced multiple myeloma.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				P. G. Richardson, E. Weller, S. Jagannath, D. E. Avigan, M. Alsina, R. L. Schlossman, A. Mazumder, N. C. Munshi, I. M. Ghobrial, D. Doss, et al. Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma J. Clin. Oncol., December 1, 2009; 27(34): 5713 - 5719. [Abstract] [Full Text] [PDF]

				J. K Kettle, K. L Finkbiner, S. E Klenke, R. D Baker, D. W Henry, and C. B Williams Initial therapy in multiple myeloma: investigating the new treatment paradigm Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 131 - 141. [Abstract] [PDF]

				D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study Blood, August 20, 2009; 114(8): 1489 - 1497. [Abstract] [Full Text] [PDF]

				A. Hoering, J. Crowley, J. D Shaughnessy Jr, K. Hollmig, Y. Alsayed, J. Szymonifka, S. Waheed, B. Nair, F. van Rhee, E. Anaissie, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols Blood, August 13, 2009; 114(7): 1299 - 1305. [Abstract] [Full Text] [PDF]

				P. G. Richardson, W. Xie, C. Mitsiades, A. A. Chanan-Khan, S. Lonial, H. Hassoun, D. E. Avigan, A. L. Oaklander, D. J. Kuter, P. Y. Wen, et al. Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy J. Clin. Oncol., July 20, 2009; 27(21): 3518 - 3525. [Abstract] [Full Text] [PDF]

				S. Deleu, M. Lemaire, J. Arts, E. Menu, E. Van Valckenborgh, I. Vande Broek, H. De Raeve, L. Coulton, B. Van Camp, P. Croucher, et al. Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma Cancer Res., July 1, 2009; 69(13): 5307 - 5311. [Abstract] [Full Text] [PDF]

				B. Sung, A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B. B. Aggarwal Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model Mol. Cancer Ther., April 1, 2009; 8(4): 959 - 970. [Abstract] [Full Text] [PDF]

				G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al. Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 520 - 531. [Abstract] [Full Text] [PDF]

				B. Barlogie, J. Epstein, and J. D. Shaughnessy Jr Going with the flow, and beyond, in myeloma Blood, November 15, 2008; 112(10): 3917 - 3918. [Full Text] [PDF]

				A. A. Argyriou, G. Iconomou, and H. P. Kalofonos Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature Blood, September 1, 2008; 112(5): 1593 - 1599. [Abstract] [Full Text] [PDF]

				I. G. Glezerman, T. Kewalramani, and K. Jhaveri Reversible Fanconi syndrome due to lenalidomide NDT Plus, August 1, 2008; 1(4): 215 - 217. [Full Text] [PDF]

				H. Rozemuller, E. van der Spek, L. H. Bogers-Boer, M. C. Zwart, V. Verweij, M. Emmelot, R. W. Groen, R. Spaapen, A. C. Bloem, H. M. Lokhorst, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect Haematologica, July 1, 2008; 93(7): 1049 - 1057. [Abstract] [Full Text] [PDF]

				A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial Blood, February 15, 2008; 111(4): 1805 - 1810. [Abstract] [Full Text] [PDF]

				Y. Dai, S. Chen, L. B. Kramer, V. L. Funk, P. Dent, and S. Grant Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells Clin. Cancer Res., January 15, 2008; 14(2): 549 - 558. [Abstract] [Full Text] [PDF]

				L. H. Wang, X. Y. Yang, X. Zhang, and W. L. Farrar Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR{gamma} cross talk with NF-{kappa}B and C/EBP Blood, December 15, 2007; 110(13): 4373 - 4384. [Abstract] [Full Text] [PDF]